🔎 Trials Near Me

Почетна › Akutna bifentipska leukemija › Оклахома

Kliničke studije za Akutna bifentipska leukemija u državi Оклахома

5 studija za Akutna bifentipska leukemija traži učesnike na lokacijama u državi Оклахома.

Gradovi u državi Оклахома

Zvanični tekst studije (na engleskom)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 2
365 Days · Оба пола · Ажурирано 27. 10. 2026. · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Oklahoma Health Sciences Center, Oklahoma City
  • Saint Francis Children's Hospital, Tulsa
Тражи се учесникФаза 3
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • University of Oklahoma Health Sciences Center, Oklahoma City
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Saint Francis Children's Hospital, Tulsa
Тражи се учесникФаза 2
Узраст од 1 до 18 · Оба пола · Ажурирано 10. 8. 2026. · NCT06390319

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

  • Saint Francis Children's Hospital, Tulsa
Тражи се учесникФаза 4
Узраст од 1 до 18 · Оба пола · Ажурирано 14. 7. 2026. · NCT06289673

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.